196205-06-8 Usage
General Description
4-Methyl-5-aminoindole is a chemical compound with the molecular formula C9H10N2. It is an indole derivative that consists of a methyl group attached to the 4-position and an amino group attached to the 5-position of the indole ring. 4-Methyl-5-aminoindole is commonly used in organic synthesis and medicinal chemistry as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and reactivity make it a valuable intermediate in the production of dyes, pigments, and other organic compounds. 4-Methyl-5-aminoindole has also been studied for its potential biological activities, including its use as a starting material for the synthesis of potential anticancer agents and as a ligand in the development of new catalysts. Overall, this compound has a wide range of applications and potential uses in the fields of chemistry and pharmacology.
Check Digit Verification of cas no
The CAS Registry Mumber 196205-06-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,2,0 and 5 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 196205-06:
(8*1)+(7*9)+(6*6)+(5*2)+(4*0)+(3*5)+(2*0)+(1*6)=138
138 % 10 = 8
So 196205-06-8 is a valid CAS Registry Number.
InChI:InChI=1/C9H10N2/c1-6-7-4-5-11-9(7)3-2-8(6)10/h2-5,11H,10H2,1H3
196205-06-8Relevant articles and documents
5- AND 6-(2-IMIDAZOLIN-2-YLAMINO) AND -(2-THIAZOLIN-2-YLAMINO)-BENZOTHIAZOLES AS ALPHA-2 ADRENERGIC LIGANDS
-
, (2008/06/13)
This invention is directed to indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
